Fundamental of Real-World Evidence Studies

The healthcare industry has been relying on traditional research approaches for a long time, but the information gained from these methods often needs to be expanded in scope.

Real-world evidence studies have the potential to provide new insights into clinical interventions and patient outcomes, giving us a clearer understanding of what works best in different scenarios. Read on to find out why This type of research is essential for making informed decisions in the healthcare sector.

There are several benefits of conducting Real-World Evidence (RWE) studies. RWE can provide insights complementary to traditional clinical trials and help generate new hypotheses about the safety and efficacy of treatments. RWE studies can also be conducted at a fraction of the cost and time of clinical trials, making them an attractive option for drug developers.

Challenges of RWE Studies

There are many challenges associated with conducting real-world evidence studies. First, it can be difficult to identify and enroll appropriate study participants. Second, data collected in the real world is often of lower quality than data collected in controlled clinical trials. It can make it difficult to draw reliable conclusions from real-world evidence studies. Third, real-world evidence studies are often conducted on small samples of patients, which can limit their statistical power and generalizability. Finally, the results of real-world evidence studies can be confounded by numerous factors, such as patients’ baseline characteristics, concomitant medications, and health status at the time of data collection.

Types of RWE Studies

  • There are three types of RWE studies: observational, interventional, and hybrid.
  • Observational studies are conducted using data already collected, such as from patient registries or electronic health records. These studies can be retrospective (looking back at past data) or prospective (collecting new data).
  • Interventional studies involve actively intervening in the care of patients to collect data. These studies can be randomized controlled trials (RCTs) or non-randomized studies.
  • Hybrid studies combine elements of both observational and interventional designs. For example, a hybrid study might use data from a registry but also include a component where patients are actively followed over time.

How to Design a Successful RWE Study

There are a few key things to keep in mind when designing a Real-World Evidence (RWE) study:

  1. Define your study population and target disease or condition. It will help you determine what data sources to use and how to select your study subjects best.
  2. Create a robust data collection plan. It should include specifying which data sources you will use, how you will collect the data, and how you will clean and prepare the data for analysis.
  3. Develop clear hypotheses and objectives. Your RWE study should answer specific questions about the effectiveness of treatments or interventions in the real world.
  4. Plan for statistical analysis and power calculation. It will ensure that your RWE study is powered to detect meaningful treatment effects.
  5. Write a detailed protocol for your RWE study. The document should outline all study aspects, from eligibility criteria to primary and secondary outcomes.
  6. Work with experienced partners. Conducting an RWE study can be complex, so it is important to partner with professional organizations or individuals who can help you design and implement the study successfully.

Conclusion

Real-world evidence studies provide invaluable insights into the effectiveness of treatments and therapies in real-world settings. They are an important part of healthcare decision-making, as they can inform decisions that lead to improved patient outcomes. We hope The article has helped you understand the importance of conducting RWE studies and how they can be used effectively in clinical practice. With their help, health professionals can better serve their patients by providing the best possible care based on reliable data.

Ceramide and its metabolites (sphingosine, 4-hydroxy-dihydro sphingosine (phytosphingosine), sphingosine-1-phosphate (S1P) phytosphingosine-1-phosphate and ceramide-1-phosphate (C1P) are lipid mediators that modulate cellular function.

 

Ceramides and structural pseudo ceramides have been formulated in skin care products and medicine to treat xerosis, psoriasis, atopic dermatitis (AD). Topically applied ceramide, with appropriate chemical formulation, forms stable liquid crystal and bilayer structures, improving permeability barrier integrity on the skin surface. Ceramide may be incorporated into lamellar bilayer structures to enhance barrier integrity in the stratum corneum. It is noted that as changes in ceramide species occur in AD and psoriasis, ceramide species uses for topical agents must be carefully considered. Acylceramide is a ceramide species essential for forming a competent barrier. A suitable selection (and amount) of ceramide is required for the preparation of an effective topical formula. Topically applied ceramide can penetrate into nucleated layers of the epidermis, in particular in barrier-compromised skin. Absorbed ceramide is hydrolyzed to a sphingoid base and FA, which are utilized in endogenous ceramide synthesis.

Oral glycosylceramide and sphingomyelin derived from plants and milk are used (as nutraceuticals) to improve skin moisture and the epidermal permeability barrier. Some oral sphingolipids are hydrolyzed by digestive enzymes and enzymes derived from intestinal microbes and absorbed through the intestinal membrane. Sphingolipids could affect gut immunity. Absorbed sphingolipids are transferred to the liver where they are further metabolized and circulated to peripheral tissues, including skin.

Source: (Uchida)